Compass Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 32
- Market Cap
- $173.3M
- Introduction
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT06150664
- Locations
- 🇺🇸
D&H Cancer Research Center, Margate, Florida, United States
🇺🇸Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 84
- Registration Number
- NCT05513742
- Locations
- 🇺🇸
Zangmeister Cancer Center, Columbus, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists & Research Institute - North, Saint Petersburg, Florida, United States
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT05506943
- Locations
- 🇺🇸
Virginia Mason Franciscan Health, Seattle, Washington, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT03881488
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States